Pharma doesnt always need a better molecule to win. Sometimes it just needs a better schedule.
Heres the uncomfortable truth behind many patent cliffs: the battle isnt only over patentsits over timing, regulatory pathways, and commercial execution.
A r…
The Authorized Generic That Beats the Patent Cliff to Market Read Post »
Most portfolios dont have a patent problem. They have a timeline problem.
The gap between a truly defensible drug patent and the listed patent that appears in the regulatory record is often wider than investors realizeand its wide enough to turn upside…
One day late. Nine figures short. What the first to file system really costs.
In patents, timing isnt a detailits destiny. A single day can mean the difference between a dominant market position and losing it before the world even realizes what happe…
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
One day late. Nine figures short.
Thats the headline lesson from a recent patent dispute in the pharmaceutical worldone where timing wasnt just important, it was existential. In a market built on years of R&D, regulatory timelines, and blockbuster …
One Day Late, Nine Figures Short: What Being the Second First-to-File Actually Costs Read Post »
The skinny label is often the earliest signal in the whole drug-patent cycle.
Most investors only start paying attention after the headline numbers appearcopycat approvals, label updates, or litigation thats already out in the open. But the real alph…
The Myth of the Stable Drug Patent Is Costing InvestorsAnd Patient AccessReal Time
In pharmaceuticals, everyone loves certainty.
Investors build models on it. Management teams defend pipelines with it. Lawyers structure deals around it. But the comfort…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Drug Patent Watch argues that stable drug patents are a mythbecause in the real world, IPRs (Inter Partes Reviews) can flip the market overnight. Heres why that matters for investors, innovators, and anyone pricing risk in healthcare.
The story we tell…
The Myth of the Stable Drug Patent: Why IPRs Change the Game Overnight Read Post »
Patent strategy has become a game of choreographynot just litigation. And if youre still treating your Paragraph IV program like a one-time decision, youre already late to the rhythm.
The latest insight from DrugPatentWatchPredictable by Design: How Br…
Predictable by Design: How Brands Outmaneuver Your Paragraph IV Strategy Read Post »
The First-Filer Trap: Why 180-Day Exclusivity Fails Without a Supply-Chain Moat
Theres a quiet misconception in generic drug strategy: that winning the first-to-file litigation clock automatically wins the market.
Pharmaceuticals dont work like that….
The First-Filer’s Trap: Why 180-Day Exclusivity Fails Without a Supply Chain Moat Read Post »
ð¨ Stop chasing blockbusters. The real margin may be sitting quietly in unloved orphan drug patents.
For years, the industrys playbook has been simple: find the next blockbuster, protect it aggressively, monetize it globally, and ride the wave. But t…
Stop Chasing Blockbusters: The High-Margin World of Unloved Orphan Drug Patents Read Post »
Get new actionable insights and updates from BiotechBlog
